首页> 外文期刊>International Journal of Clinical Oncology >Sunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT gene
【24h】

Sunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT gene

机译:耐舒尼替尼的胃肠道间质瘤在KIT基因的激活环中具有顺式突变

获取原文
获取原文并翻译 | 示例
       

摘要

Although sunitinib malate has shown significant clinical effect on imatinib-resistant gastrointestinal stromal tumors, with acceptable tolerability and improved prognosis for the patients, the mechanism of resistance to the drug is still under investigation.
机译:尽管苹果酸舒尼替尼对伊马替尼耐药的胃肠道间质瘤已显示出显着的临床效果,具有可接受的耐受性并改善了患者的预后,但对这种药物的耐药机制仍在研究中。

著录项

  • 来源
    《International Journal of Clinical Oncology》 |2009年第2期|143-149|共7页
  • 作者单位

    Department of Surgery Osaka University Graduate School of Medicine 2-2 Yamadaoka Suita Osaka 565-0871 Japan;

    Department of Surgery Osaka University Graduate School of Medicine 2-2 Yamadaoka Suita Osaka 565-0871 Japan;

    Department of Surgery Osaka University Graduate School of Medicine 2-2 Yamadaoka Suita Osaka 565-0871 Japan;

    Division of Gastrointestinal Oncology/Digestive Endoscopy National Cancer Center Hospital East Chiba Japan;

    Department of Medical Oncology National Cancer Center Hospital Tokyo Japan;

    Department of Gastroenterology Hokkaido University Graduate School of Medicine Hokkaido Japan;

    Department of Surgery Osaka University Graduate School of Medicine 2-2 Yamadaoka Suita Osaka 565-0871 Japan;

    Department of Surgical Pathology Hyogo Medical College Kobe Japan;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    Acquired resistance; KIT; Imatinib; Sunitinib; Mutation;

    机译:获得性耐药;KIT;伊马替尼;舒尼替尼;突变;
  • 入库时间 2022-08-18 00:10:38

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号